PRNAF Stock Chart & Stats
$0.40
-$0.10(-22.22%)
At close: 4:00 PM EDT
$0.40
-$0.10(-22.22%)
Day’s Range― - ―
52-Week Range$0.06 - $0.55
Previous CloseN/A
Volume3.16K
Average Volume (3M)36.00
Market Cap
$82.21M
Enterprise Value$32.34
Total Cash (Recent Filing)$37.32M
Total Debt (Recent Filing)$193.47K
Price to Earnings (P/E)―
Beta2.93
Next Earnings
Mar 04, 2027EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding220,215,360
10 Day Avg. Volume0
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)2.83
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$0.68Price Target Upside70.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$2.56M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Capital BufferMinimal debt reduces financial risk and interest burden, giving Alterity greater flexibility to fund clinical development. The existing asset and equity buffer may help sustain operations, although continued losses could erode it over time.
Strengthened Intellectual PropertyNew composition-of-matter protection can strengthen ATH434’s commercial defensibility and future partnering appeal. Longer exclusivity may support eventual pricing power and reduce substitution risk if clinical and regulatory milestones are achieved.
Disease-Modifying Clinical StrategyA proprietary oral therapy aimed at disease biology rather than symptom control could address substantial unmet need across neurodegenerative disorders. Success would create potential expansion beyond one indication, though development remains unproven.
Bears Say
No Current Commercial RevenueThe absence of product revenue leaves the company without a recurring commercial earnings base and makes financial performance dependent on clinical progress. Persistent losses will continue until an asset is approved, partnered, or commercialized.
Persistent Cash BurnOngoing operating and free-cash-flow deficits indicate that Alterity cannot currently fund development from operations. Continued trials and corporate costs therefore require external capital, creating funding and dilution risk over the medium term.
Negative Returns On EquityNegative returns on equity show that invested capital is not yet generating economic returns. If clinical progress does not produce a commercial inflection, repeated losses and new financing could reduce the value attributable to existing shareholders.
Alterity Therapeutics News
PRNAF FAQ
What was Alterity Therapeutics’s price range in the past 12 months?
Alterity Therapeutics lowest stock price was $0.06 and its highest was $0.55 in the past 12 months.
What is Alterity Therapeutics’s market cap?
Alterity Therapeutics’s market cap is $82.21M.
When is Alterity Therapeutics’s upcoming earnings report date?
Alterity Therapeutics’s upcoming earnings report date is Mar 04, 2027 which is in 185 days.
How were Alterity Therapeutics’s earnings last quarter?
Alterity Therapeutics released its earnings results on Feb 25, 2026. The company reported -$0.032 earnings per share for the quarter, missing the consensus estimate of -$0.021 by -$0.012.
Is Alterity Therapeutics overvalued?
According to Wall Street analysts Alterity Therapeutics’s price is currently Undervalued.
Does Alterity Therapeutics pay dividends?
Alterity Therapeutics does not currently pay dividends.
What is Alterity Therapeutics’s EPS estimate?
Alterity Therapeutics’s EPS estimate is >-0.01.
How many shares outstanding does Alterity Therapeutics have?
Alterity Therapeutics has 220,215,360 shares outstanding.
What happened to Alterity Therapeutics’s price movement after its last earnings report?
Alterity Therapeutics reported an EPS of -$0.032 in its last earnings report, missing expectations of -$0.021. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alterity Therapeutics?
Currently, no hedge funds are holding shares in PRNAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.68 (70.50% Upside)
$0.68 (70.50% Upside)
Blogger Sentiment
Bullish
PRNAF Sentiment 97%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alterity Therapeutics
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
PRNAF Stock 12 Month Forecast
Average Price Target
$0.68
▲(70.50% Upside)
Actinogen Medical
―
Cynata Therapeutics Limited
―
Tryptamine Therapeutics
―
Living Cell Technologies
―
Neuren Pharmaceuticals Limited
―